stoxline Quote Chart Rank Option Currency Glossary
  
Kronos Bio, Inc. (KRON)
1.01  -0.02 (-1.94%)    04-19 16:00
Open: 1.01
High: 1.04
Volume: 119,687
  
Pre. Close: 1.03
Low: 0.9855
Market Cap: 61(M)
Technical analysis
2024-04-19 5:10:36 PM
Short term     
Mid term     
Targets 6-month :  1.43 1-year :  1.61
Resists First :  1.22 Second :  1.37
Pivot price 1.15
Supports First :  0.98 Second :  0.81
MAs MA(5) :  1.06 MA(20) :  1.17
MA(100) :  1.17 MA(250) :  1.35
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.5 D(3) :  7.6
RSI RSI(14): 36
52-week High :  2.28 Low :  0.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KRON ] has closed above bottom band by 12.1%. Bollinger Bands are 24.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.04 - 1.05 1.05 - 1.05
Low: 0.97 - 0.98 0.98 - 0.98
Close: 1 - 1.01 1.01 - 1.02
Company Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Headline News

Wed, 17 Apr 2024
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase ... - The Globe and Mail

Wed, 03 Apr 2024
Kronos Bio (NASDAQ:KRON) Trading Down 8% - MarketBeat

Wed, 27 Mar 2024
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Thu, 21 Mar 2024
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results - Yahoo Finance

Thu, 07 Mar 2024
Kronos cuts 21% of workforce, extends cash runway into 2H 2026 (NASDAQ:KRON) - Seeking Alpha

Thu, 07 Mar 2024
Kronos Bio Implements Workforce Reduction to Extend Financial Runway - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 60 (M)
Shares Float 44 (M)
Held by Insiders 19.5 (%)
Held by Institutions 44.6 (%)
Shares Short 665 (K)
Shares Short P.Month 600 (K)
Stock Financials
EPS -1.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.7
Profit Margin 0 %
Operating Margin -994.4 %
Return on Assets (ttm) -28.9 %
Return on Equity (ttm) -55.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.1
EBITDA (p.s.) -1.92
Qtrly Earnings Growth 0 %
Operating Cash Flow -79 (M)
Levered Free Cash Flow -44 (M)
Stock Valuations
PE Ratio -0.52
PEG Ratio 0
Price to Book value 0.37
Price to Sales 9.64
Price to Cash Flow -0.78
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android